References
- Sánchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 2003; 167:353–362.
- Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20:131–137.
- Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005; 21:1659–1668.
- Grundemar L, Wohlfahrt B, Lagerstedt C, Bengtsson F, Eklundh G. Symptoms and signs of severe citalopram overdose. Lancet 1997; 349:1602.
- Personne M, Sjöberg G, Persson H. Citalopram overdose-review of cases treated in Swedisch hospitals. J Toxicol Clin Toxicol 1997; 35:237–240.
- Engebretsen KM, Harris CR, Wood JE. Cardiotoxicity and late onset seizures with citalopram overdose. J Emerg Med 2003; 25:163–166.
- Lo Vecchio F, Watts D, Winchell J, Knight J, McDowell T. Outcomes after supratherapeutic escitalopram ingestions. J Emerg Med 2006; 30:17–19.
- Forrester MB. Escitalopram ingestions reported to Texas poison control centers, 2002–2005. Hum Exp Toxicol 2007; 26:473–482.
- Ho R, Norman R, van Veen M, Anderson I. A 3-year review of citalopram and escitalopram ingestions (abstract). J Toxicol Clin Toxicol 2004; 42:746.
- Hayes BD, Klein-Schwartz W, Clark RF, Muller AA, Miloradovich JE. Comparison of toxicity of acute overdoses with citalopram and escitalopram. J Emerg Med 2008 Dec 10; Epub ahead of print.
- Stedtler U, Hofmann-Walbeck P, Prasa D, Rauber-Luethy C, Reinecke HJ. Amlodipine: collection and analysis of case data in the society of clinical toxicology of German speaking countries (GfKT). EAPCCT Abstracts. J Toxicol Clin Toxicol 2008; 46:351–421.
- Persson HE, Sjöberg GK, Haines JA, Pronczuk de Garbino J. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol 1998; 36:205–213.
- Van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009; 54:404–408.
- Waring WS, Gray JA, Graham A. Predictive factors for generalized seizures after deliberate citalopram overdose. Br J Clin Pharmacol 2008; 66:861–865.
- Bagdy G, Kecskemeti V, Riba P, Jakus R. Serotonin and epilepsy. J Neurochem 2007; 100:857–873.
- Trindade-Filho EM, de Castro-Neto EF, de A Carvalho R, Lima E, Scorza FA, Amado D, Naffah-Mazzacoratti Mda G, Cavalheiro EA. Serotonin depletion effects on the pilocarpine model of epilepsy. Epilepsy Res 2008; 82:194–199.
- Meldrum B. Pharmacology of GABA. Clin Neuropharmacol 1982; 5:293–316.
- Ago J, Ishikawa T, Matsumoto N, Ashequr Rahman M, Kamei C. Mechanism of imipramine-induced seizures in amygdala-kindled rats. Epilepsy Res 2006; 72:1–9.
- Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R, Pötzi C, Holik A, Spindelegger C, Asenbaum S, Dudczak R, Tauscher J, Kasper S. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) 2006; 188:263–272.
- Klein N, Sacher J, Geiss-Granadia T, Mossaheb N, Attarbaschi T, Lanzenberger R, Spindelegger C, Holik A, Asenbaum S, Dudczak R, Tauscher J, Kasper S. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl) 2007; 191:333–339.
- Hyttel J. Citalopram–pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6:277–295.
- Jobe PC, Browning RA. The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav 2005; 7:602–619.
- Ye ZY, Lu YG, Sun H, Cheng XP, Xu TL, Zhou JN. Fluoxetine inhibition of glycine receptor activity in rat hippocampal neurons. Brain Res 2008; 1239:77–84.
- Signorini S, Liao YJ, Duncan SA, Jan LY, Stoffel M. Normal cerebellar development but susceptibility to seizures in mice lacking G protein-coupled inwardly rectifying K+ channel GIRK2. Proc Natl Acad Sci U S A 1997; 94:923–927.
- Kobayashi T, Washiyama K, Ikeda K. Modulators of G protein-activated inwardly rectifying K+ channels: potentially therapeutic agents for addictive drug users. Ann N Y Acad Sci 2004; 1025:590–594.